https://doi.org/10.55788/8d579876
GPP is a rare but potentially life-threatening inflammatory skin disease characterised by widespread eruption of sterile pustules, which has recently been reclassified as a superficial/epidermal neutrophilic disease [1–3]. The antibody spesolimab specifically targets the IL-36 receptor, which plays a key role in GPP pathogenesis, and is approved for the treatment of GPP flares.
Previously, spesolimab has been evaluated for the prevention of flares in the randomised, placebo-controlled, phase 2 Effisayil 2 trial (NCT04399837). Currently, Prof. Matthias Augustin (University Medical Center Hamburg-Eppendorf, Germany) presented an analysis of Effisayil 2, which assessed the effect of high-dose spesolimab (i.e. 600 mg loading dose followed by 300 mg every 4 weeks) or placebo on GPP lesions using both subscores and the total score of the GPP Physician Global Assessment (GPPGA) scale [4]. GPPGA subscores for erythema, pustulation, and scaling/crusting as well as GPPGA total score were compared between participants receiving high-dose spesolimab and placebo. At baseline, the subscores were balanced between the groups. “Only 23% of participants had an IL36RN mutation,” Prof. Augustin added.
After treatment initiation with spesolimab, the proportion of participants with a GPPGA score of 0 (i.e. 0 for all 3 components of erythema, pustulation, and scaling) increased, whereas the score remained similar in the placebo group at week 4. In addition, the proportion of participants with GPP flares was lower with high-dose spesolimab compared with placebo.
Moreover, the agent showed long-term efficacy in managing skin manifestations. A greater proportion of participants with a GPPGA total score of 0 was achieved and maintained with spesolimab compared with placebo over 48 weeks. The superiority of spesolimab was evident in each subscore compared with placebo up to week 48. Importantly, no new flares were observed with high-dose spesolimab after week 4.
- Choon S, et al. Am J Clin Dermatol 2022;23(Suppl 1):S21–29.
- Burden AD, et al. Am J Clin Dermatol 2022;23 (Suppl 1):S39–50.
- Krueger J, et al. Am J Clin Dermatol 2022;23 (Suppl 1):S51–64.
- Augustin M. Effect of high-dose subcutaneous spesolimab on skin manifestations: Results from the pivotal Effisayil 2 trial of flare prevention in generalized pustular psoriasis. FC05.2, EADV Congress 2023, 11–14 October, Berlin, Germany.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Drug survival of guselkumab and risankizumab seems superior to other biologics Next Article
Dual IL-17 blockade yields efficacy on joints and skin »
« Drug survival of guselkumab and risankizumab seems superior to other biologics Next Article
Dual IL-17 blockade yields efficacy on joints and skin »
Table of Contents: EADV 2023
Featured articles
Tapinarof on course to become a new topical treatment in AD
AD and Eczema in 2023
Tapinarof on course to become a new topical treatment in AD
Upadacitinib provides sustained skin clearance in adolescents and adults with AD
Sustained deep clinical and itch responses with novel IL-13 inhibitor
IL-13 inhibitor shows potential in atopic dermatitis
Encouraging results for amlitelimab in atopic dermatitis
Chronic hand eczema: patients share similar molecular signatures regardless of AD status
Severe hand eczema: dupilumab could be a future treatment
Psoriasis News
Dual IL-17 blockade yields efficacy on joints and skin
High-dose subcutaneous spesolimab prevents GPP flares up to week 48
Drug survival of guselkumab and risankizumab seems superior to other biologics
IL-23 blockers may lower the risk of developing inflammatory and psoriatic arthritis
First-in-class oral IL-23 inhibitor safe and effective for moderate-to-severe plaque psoriasis
Hidradenitis Suppurativa: End of the Diagnostic and Therapeutic Draught
Skin tape stripping allows a novel precision medicine approach in HS
Nanobodies: A novel way to treat HS
Anti-IL17 blockade leads to maintained pain reduction in patients with HS
Vitiligo: Novel Treatment Options
JAK1 inhibition: a promising forthcoming treatment option in vitiligo
Vitiligo: Continuation of topical ruxolitinib successful in many initial non-responders
Alopecia Areata: Novel Developments
JAK3/TEC inhibition achieves clinically meaningful responses in AA
Alopecia areata: remarkable regrowth rates with deuruxolitinib
Botanical drug solution improves hair regrowth in children and adolescents with AA
What’s New in Other Disease Entities
Nemolizumab shows high success rates in prurigo nodularis
Remibrutinib reduces itch, sleep problems, and activity impairment in patients with CSU
Innovative wound gel reduces frequency of painful dressing changes in epidermolysis bullosa
Best of the Posters
Women with psoriasis face increased adverse effects with systemic therapy
Improved AI tool shows high sensitivity rates in skin cancer detection
Dermoscopy training combined with AI significantly improves skin cancer detection
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy